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Objectives. We sought to examine completed 10-year survival
and event-free survival in patients with stable and unstable
angina pectoris treated by coronary balloon angioplasty.
Background. Patients with unstable angina are at increased
risk for recurrent acute coronary events.
Methods. The study included 208 consecutive patients (133 with
stable and 75 with unstable angina pectoris) undergoing angio-
plasty from 1984 to 1986. The balloon crossed the lesion in 185
patients (121 with stable and 64 with unstable angina pectoris).
Angioplasty was performed in patients with unstable angina
pectoris 12 6 15 days (median 8) after symptom onset. Patients
with unstable angina pectoris were classified retrospectively into
Braunwald class I (n 5 3), class II (n 5 20), class III (n 5 28),
class B (n 5 52) and class C (n 5 12). Follow-up data were
obtained from hospital charts, telephone interview and official
death certificates where applicable. The study had >80% power to
detect a clinically significant 20% difference in survival and a 20%
difference in event-free survival between the stable and unstable
patient groups.
Results. Despite similar baseline characteristics, early (40-day)
mortality was slightly higher in patients with unstable angina
(4.7% [3 of 64 patients] vs. 0.8% [1 of 121 patients], p 5 NS).
Long-term outcome was not different, because survival curves
were parallel thereafter (10-year survival was 83% for those with
stable and 77% for those with unstable angina, p 5 NS). Survival
free of myocardial infarction or coronary artery bypass graft
surgery at 10 years was 53% in patients with stable and 47% in
patients with unstable angina (p 5 NS), and survival free of
infarction, bypass surgery or repeat angioplasty was 32% for both
groups at 10 years. In patients with Braunwald class III unstable
angina, 10-year survival was 80%, as compared with 85% in other
patients with unstable angina, due to the early hazard (p 5 NS).
Survival and event-free survival were similar in patients who had
had a recent myocardial infarction (Braunwald class C) and in
patients with acute electrocardiographic changes. Repeat hospital
admissions were not more frequent in patients with unstable
angina (3.1 6 3.5 vs. 3.0 6 2.6, p 5 NS).
Conclusions. Ten-year survival and event-free survival were
similar in patients with stable and unstable angina pectoris
treated by coronary balloon angioplasty, with no evidence of an
increased rate of recurrent cardiovascular events in the unstable
group.
(J Am Coll Cardiol 1998;32:1603–9)
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The clinical syndrome of unstable angina pectoris defines a
group of patients with coronary disease who are at increased
risk of fatal and nonfatal myocardial infarction (MI) and
sudden cardiac death. More than 20% of patients with unstable
angina have a non–Q wave MI during the initial hospital
period, and another 3% have a new episode of MI in the
following 6 weeks (1). Unstable angina is associated with
in-hospital or 6-week mortality of 1.5% to 2.5% (1,2) and
1-year mortality of up to 10% (2). Recurrent hospital admis-
sion is necessary in one-third of the patients.
Unstable angina results from a critical reduction in coro-
nary blood flow, usually after an acute change in the pathology
of a coronary lesion. Possible mechanisms underlying plaque
destabilization include endothelial damage, erosion or rupture
of the fibrous cap and changes in plaque cellularity and
vascularity (3). Rupture of a plaque is associated with platelet
aggregation, intermittent generation and lysis of thrombus and
episodes of distal microembolization, which together with
changes in coronary vascular tone produce instability of coro-
nary blood flow (4–7). In conjunction with the localized
pathophysiologic event, patients with unstable angina show
evidence of a systemic response, including activation of the
coagulation system and an acute systemic inflammatory reac-
tion (8–10) mediated by the immune system (11). The hyper-
coagulable state and systemic inflammatory markers may per-
sist for at least 6 months, even in patients who have no further
clinical episodes, and may predate the episode of unstable
angina pectoris (12) or acute MI and may be a risk factor for
its occurrence (13–15).
Revascularization using percutaneous transluminal coro-
nary angioplasty provides an effective therapeutic modality in
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patients with unstable angina and coronary lesions amenable
to balloon dilation (16–25). The acute local and more pro-
longed systemic processes operative in the patient with unsta-
ble angina could form the basis for an increased rate of
recurrent events in patients with unstable angina pectoris.
However, although patients with unstable angina were in-
cluded and reported in angioplasty follow-up studies (21,26–
30), the question of long-term outcome after angioplasty for
unstable angina pectoris, with appropriate subset grouping and
analysis, has not been addressed in detail. This study examined
the completed 10-year outcome in patients with unstable
angina pectoris treated by coronary balloon angioplasty, taken
from a cohort of consecutive patients entered prospectively in
the mid-1980s into the Lady Davis Carmel Medical Center
Interventional Registry. We compared the results with those of
patients undergoing angioplasty for stable angina pectoris
during the same period to determine whether dilation of the
culprit lesion alters the prognosis or whether patients with
unstable angina have an adverse long-term prognosis due to
recurrent unstable or acute events.
Methods
Patient group. During the period 1984 to 1986, 227 pa-
tients underwent percutaneous transluminal coronary angio-
plasty for coronary artery disease in a single cardiology depart-
ment. Survival data were available for 224 of the patients
(98.6%) (three foreign nationals could not be traced), and late
events and symptomatic status were obtained in 97% of the
survivors. In 14 patients the procedure was performed in the
context of acute MI without recurrent angina pectoris or
evidence of recurrent ischemia, and these patients were re-
moved from the present analysis. Two other patients in whom
the classification of stable and unstable angina was not clear
were excluded: one who underwent angioplasty in close prox-
imity to bypass surgery for a technical graft problem and
another who underwent angioplasty after atypical chest pain
related to a noncardiac interventional stress.
Unstable angina was defined as a recent deterioration in
anginal symptoms leading to hospital admission or presenta-
tion to the emergency room with pain at rest. Of the 208
patients in this study, 75 (36%) had unstable and 133 (64%)
had stable angina pectoris. The lesion could not be crossed by
the angioplasty wire or balloon catheter in 11 patients (15%) in
the unstable and 12 patients (9%) in the stable group (p 5
NS), so that dilation was actually performed in 185 patients (64
with unstable and 121 with stable angina).
The mean time from symptom onset to angioplasty in
patients with unstable angina was 12 6 15 days (median 8).
Baseline patient characteristics. The baseline characteris-
tics of patients with stable and unstable angina pectoris are
given in Table 1. There was no difference between the two
groups with regard to age, gender, diabetes mellitus, hyperten-
sion and the presence of multivessel coronary artery disease.
Single-, double- or triple-vessel disease was defined as the
number of systems (left anterior descending, circumflex or
right coronary artery) with one or more narrowings of .60% in
a coronary artery or any of its major branches, or both, in the
worst angiographic view. A slightly larger number of patients
with unstable angina (p 5 NS) had undergone a previous MI.
Almost 10% of patients in both groups had undergone previ-
ous coronary artery bypass graft surgery.
Subclassification of patients with unstable angina pectoris.
At the time the patients in this study underwent angioplasty,
there was no generally accepted definition of patient subsets
regarding unstable angina pectoris. However, patients were
classified retrospectively with the aid of the medical and
nursing records at the time of angioplasty, according to the
Braunwald classification (31). The severity of angina was
classified as class III (occurring at rest and within 48 h of
angioplasty) in 28 (55%) of 51 patients with available data,
class II (at rest in the previous month but not in the 48 h before
angioplasty) in 20 patients (39%) and class I (occurring on
minimal or rapidly decreasing effort but not at rest) in 3
patients (6%). The clinical circumstances were classified as
class C (Q wave MI during the 2 weeks before angioplasty) in
12 (19%) of the 64 patients (7 of whom had class III and 2 of
whom had class II anginal severity; insufficient data in 3) and as
class B in the remaining 52 patients (81%) (instability not due
to an extracardiac condition); (21 of whom had class III, 18 of
whom had class II and 3 of whom had class I anginal severity;
data unavailable in 10). The majority of patients were receiving
combined therapy for angina pectoris before hospital admis-
sion (44 [86%] of 51 patients with complete data with two or
more antianginal drugs before hospital admission and only 3
[6%] not receiving medication). New electrocardiographic
(ECG) ST segment–T wave changes were recorded during
chest pain in 31 (61%) of 51 patients.
Angioplasty procedure. Angioplasty was performed using
standard techniques and pharmacotherapy at the time. Phar-
macotherapy included pretreatment with antiplatelet drugs
(aspirin 100 to 325 mg daily), intravenous heparin (10,000 to
25,000 U during and in most patients for 8 to 24 h after the
Table 1. Baseline Characteristics of Patients With Stable and
Unstable Angina Pectoris
Unstable Angina
(n 5 64)
Stable Angina
(n 5 121) p Value
Age (yrs) 58.4 6 9.2 55.9 6 10.0 NS
Male 45 (70.3%) 94 (77.7%) NS
Previous infarction 34 (53.1%) 52 (43%) NS
Multivessel coronary
artery disease
33 (51.6%) 62 (51.2%) NS
Previous coronary artery
bypass graft surgery
6 (9.4%) 10 (8.3%) NS
Diabetes mellitus 13 (20.6%) 25 (21%) NS
(n 5 63) (n 5 119)
History of hypertension 20 (31.7%) 43 (36.1%) NS
(n 5 63) (n 5 119)
Data are presented as the mean value 6 SD or number (%) of patients.
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procedure) and intravenous, intracoronary and/or sublingual
nitrates in a dose determined by the attending cardiologist
during and after the procedure. After angioplasty patients
were treated with aspirin and long-acting nitrates for at least 3
to 6 months, unless contraindicated.
In the 185 patients in whom the lesion was crossed,
angioplasty was successful (dilation of a major vessel consid-
ered responsible for symptoms with #50% residual narrowing
and no major untoward event or urgent bypass surgery) in 59
(92%) of 64 patients with unstable angina and 119 (98%) of
121 patients with stable angina (p 5 0.05) (Table 2). The
number of systems and vessels dilated was similar between the
two patient groups. In 61% of the patients in both groups,
revascularization was complete (no residual lesions .60%).
Patient follow-up. Procedural outcome was recorded at the
time of angioplasty in all patients. Follow-up data were ob-
tained from hospital charts and supplemented by a structured
telephone interview with the patient or one of his or her
immediate relatives conducted by a single cardiologist. This
was followed by specific inquiry, as necessary, to ascertain the
functional capacity at the time of follow-up, or in the case of
death, to define its cause. When information was not available,
the cause of death was obtained from the official death
certificate. Survival and event-free survival were recorded at a
mean of 9.5 6 0.6 years. Survival was subsequently ascertained
10 to 12 years after the angioplasty procedure (mean 11.1 6 0.7
years) for all 185 patients who actually underwent dilation.
Statistical analysis. Survival and event-free survival were
assessed by life-table analysis using the Kaplan-Meier method,
and survival curves were compared using the log-rank test.
Categoric variables were compared by using the chi-square test
and continuous variables by using the Student t test.
A 20% difference in survival and a 20% difference in
event-free survival between the stable and unstable patient
groups over 10 years were considered to be clinically signifi-
cant. The study had .80% power to detect such difference in
10-year survival, given an 83% survival rate in the stable group
and a two-sided alpha error of 0.05. Given an event-free
survival rate of 32% at 10 years in the stable group, we
calculated a power of .80% to detect a 20% difference in
event-free survival (32).
Results
Patients in whom the lesion was not crossed. There were
no procedural or early deaths in the 23 patients in whom the
lesion could not be crossed. One patient in the stable group
and three patients in the unstable group had a periprocedural
infarction. Early bypass surgery was performed in four patients
(33%) with stable and four patients (36%) with unstable
angina (p 5 NS) in whom angioplasty was unsuccessful.
Patient survival. Short-term mortality (40 days) tended to
be higher in patients with unstable angina (4.7% [3 of 64
patients] vs. 0.8% [1 of 121 patients], p 5 NS) owing to a
relatively higher early mortality in a small group of very ill
patients with a recent MI, postinfarction angina and heart
failure (Braunwald class IIIC).
The long-term survival is shown in Figure 1. After the small,
early dip in survival in the unstable group, the curves remained
almost parallel throughout the long-term follow-up period.
Life-table survival at 5 years was 90.6% for the unstable and
98.0% for the stable group, and at 10 years it was 76.6% for the
unstable and 82.6% for the stable group (p 5 NS).
Event-free survival. Life-table event-free survival without
an MI or bypass surgery was 76.6% at 5 years and 47% at 10
years in the unstable group and 86.8% at 5 years and 52.6% at
10 years in the stable group (p 5 NS). The curves were linear,
showing an unchanged and almost identical event rate
throughout the follow-up period. When repeat angioplasty was
added to the recurrent events (Fig. 1), the combined recurrent
event rates remained very similar between both groups, but
there was an increased early event rate in the first year due to
repeat angioplasty procedures, the curves becoming less steep
subsequently. Combined event-free survival rates at 5 years
and 10 years were 56.3% and 32.0% for unstable and 62.8%
and 32.0% for stable angina, respectively (p 5 NS). When the
incidence of recurrent MI, bypass surgery or repeat angioplasty
procedures was examined individually, there were no signifi-
Table 2. Procedural Variables
Unstable Angina
(n 5 64)
Stable Angina
(n 5 121) p Value
Mean no. (6SD) of
systems dilated
1.2 6 0.38 1.2 6 0.48 NS
Number of systems dilated
One 53 (82.8%) 96 (79.3%)
Two 11 (17.2%) 22 (18.2%) NS
Three 0 3 (2.5%)
Successful procedure 59 (92.2%) 119 (98.3%) 0.05
Complete
revascularization*
31 (61%) 74 (61%) NS
*No residual major lesions .60%. Data are presented as mean value 6 SD
or number (%) of patients.
Figure 1. Kaplan-Meier curves of survival and event-free survival
(alive without MI, bypass surgery or repeat angioplasty) for patient
cohorts with stable and unstable angina pectoris. After a small, early
fall in survival of patients with unstable angina, the curves remained
parallel throughout the follow-up period. Event-free survival curves
were similar in both patient cohorts.
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cant differences between the stable and unstable angina
groups.
Subset analysis in patients with unstable angina pectoris.
Long-term survival and event-free survival rates for patients
with stable angina and different subsets of patients with
unstable angina are given in Table 3. In patients who under-
went angioplasty within 2 days of the last episode of chest pain
(Braunwald class III), 5- and 10-year survival rates were 90%
and 80.0% as compared with 95.7% and 84.6% in the other
patients with unstable angina (p 5 NS) (Fig. 2) and 98% and
82.6% in the stable group (p 5 NS). Combined event-free
survival at 5 and 9.7 years was not significantly different from
that in other patients with unstable angina (60.7% and 42.9%
vs. 47.8% and 43.5%) or from that in patients with stable
angina. In the 12 patients who underwent angioplasty for
postinfarction angina (Braunwald class C), long-term survival
was slightly but not significantly lower than that in other
patients with unstable angina (66.7% vs. 82.7% at 10 years) or
stable angina. The combined event-free survival rate in Braun-
wald class C was also not significantly different from that of
other patients with unstable angina. Those with unstable
angina in whom ischemic ECG changes were recorded before
angioplasty (n 5 31, 61%) had a 5- and 10-year survival rate of
90.3% and 80.6% as compared with 95.0% and 85.0% in other
patients with unstable angina (Fig. 3) (p 5 NS). Event-free
survival at 5 and 9.7 years was also not different in patients with
and without ischemic ECG changes at the time of the acute
event.
The mean number of repeat cardiac hospital admissions
during the follow-up period was similar in the unstable and
stable groups (3.1 6 3.5 per patient for unstable vs. 3.0 6 2.6
for stable angina) (p 5 NS). Functional class at the latest
Table 3. Long-Term Outcome of Patients With Stable and Unstable Angina
n
Survival (%)
Alive, No MI, No
CABG (%)
Alive, No MI, No
CABG, No PTCA (%)
5 yrs 10 yrs 5 yrs 9.7 to 10 yrs 5 yrs 9.7 to 10 yrs
Stable angina 121 98.0 82.6 86.8 52.6 (10 yrs) 62.8 32.0 (10 yrs)
Unstable angina 64 90.6 76.6 76.6 47.0 (10 yrs) 56.3 32.0 (10 yrs)
Severity*
Classes I and II 23 95.7 84.6 78.3 53.3 (9.7 yrs) 47.8 43.5 (9.7 yrs)
Class III 28 90.0 80.0 75.0 60.7 (9.7 yrs) 60.7 42.9 (9.7 yrs)
Circumstances*
Class B 52 94.2 82.7 75.0 58.6 (9.7 yrs) 51.9 42.3 (9.7 yrs)
Class C 12 75.0 66.7 58.3 50.0 (9.7 yrs) 50.0 31.3 (9.7 yrs)
Ischemic ECG changes
Ischemia 31 90.3 80.6 77.4 58.1 (9.7 yrs) 70.4 56.0 (9.7 yrs)
No ischemia 20 95.0 85.0 75.0 58.2 (9.7 yrs) 55.3 55.3 (9.7 yrs)
*According to the Braunwald classification. All group and subgroup comparisons were not significant (log-rank test).
CABG 5 coronary artery bypass graft surgery; ECG 5 electrocardiographic; MI 5 myocardial infarction; PTCA 5
percutaneous transluminal coronary angioplasty.
Figure 2. Kaplan-Meier curves of survival and event-free survival in
patients with Braunwald class II and class III unstable angina. There
was a higher early mortality and event rate in patients with class III
unstable angina but no further excess mortality or recurrent events
during the follow-up period.
Figure 3. Kaplan-Meier curves of survival and event-free survival in
patients with unstable angina with and without acute ischemic ECG
changes. There was a slightly higher early mortality in patients with
acute ischemic ECG changes but no further excess mortality during the
follow-up period. Event-free survival was similar in both groups.
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follow-up in surviving patients was almost identical in patients
with unstable and stable angina, with two-thirds in functional
class I or II (New York Heart Association) (33 [68.8%] of 48
patients with unstable angina and 67 [67%] of 100 patients with
stable angina) (p 5 NS).
Discussion
The essential findings of the study were that despite an early
hazard in high risk patients, the overall long-term survival and
event-free survival rates in patients with unstable angina
pectoris were very good and not different from that of patients
with stable angina. The outcome was similar irrespective of the
timing of angioplasty in relation to the onset of the acute
clinical syndrome or the last episode of rest pain. These results,
together with those reported by Ruygrok et al. (30), implied
that unstable angina pectoris was a short-lived process limited
to one or more particular coronary lesions and that on a
practical level, despite probable systemic phenomena, angio-
plasty seems to be followed by vascular healing and plaque
restabilization.
Management of patients with unstable angina pectoris.
Medical treatment with aspirin has been effective in reducing
the event rate in patients with unstable angina pectoris (33,34),
and the addition of heparin and low-molecular-weight heparin
provided further benefit (35,36). Antiplatelet glycoprotein
IIb/IIIa inhibitors decreased acute events both before and after
coronary intervention (37–39). The prognosis of unstable
angina may differ depending on the clinical presentation (40).
Detection of minor myocardial necrosis by troponin T assay
identified patients who may benefit from prolonged antithrom-
botic therapy (36). Coronary artery bypass surgery improved
2-year survival in patients with unstable angina who had
reduced left ventricular function (27) and improved survival at
8 years in patients considered to be at high risk (29).
Angioplasty for unstable angina pectoris. Increased risks
were initially reported in patients undergoing angioplasty for
unstable angina pectoris, due to an increased incidence of
thrombus and instability of the plaque (16). We usually
attempted to stabilize patients before angiography, although it
is not clear (41,42) whether early or late outcome is different in
these patients as compared with those undergoing an earlier
intervention. Stammen et al. (43) performed angioplasty in
patients with unstable angina at a mean of 15 days (range 1 to
76) after hospital admission and reported a similar 6-month
outcome to that in patients with stable angina. Coronary
angioplasty has proven to be effective (16,23,25,44), even
though angioplasty of the obstructive coronary lesion does not
prevent the systemic reaction and its local disruptive nature
could amplify it.
A higher incidence of restenosis after balloon angioplasty in
patients with unstable angina has been described by some
investigators (21,45) but not all (23). Local lesion characteris-
tics may influence the early response to angioplasty and the
late event rate (23,46–49). In the National Heart, Lung, and
Blood Institute’s Angioplasty Registry, the cumulative event
rate at 2 years was the same for patients with unstable and
stable angina (44), but at 5 years a higher crude mortality rate
was reported in patients with rest angina than that in unstable
angina patients without rest angina and particularly in those
with postinfarction angina (50). This study highlighted the
potential early hazard in patients with class IIIB unstable
angina in the mid-1980s, but showed quite clearly that the later
course is no different from that of patients with stable angina.
Potential study limitations. There are several limitations
to this study. The study dealt with a relatively small sample
size, and this is particularly disadvantageous regarding sub-
group analysis. However, because baseline characteristics and
the extent of disease were similar in patients with stable and
unstable symptoms and primary treatment was the same, the
results do carry prognostic import, particularly in view of the
long follow-up period in this patient cohort. The study had
.80% power to detect a 20% difference in survival and
event-free survival between patients with stable and unstable
angina pectoris; subgroup analysis should be interpreted with
caution.
We have no knowledge of the pathophysiology at the time
of the acute event in the individual patients in this study. There
were probably a number of pathophysiologic mechanisms
involved, differing from patient to patient and possibly with
each having a different prognosis. Subset analysis using the
Braunwald classification may have corrected for such differ-
ences to some extent. It is likely that in the present era of
stents, low-molecular-weight heparin (51,52) and platelet gly-
coprotein IIb/IIIa receptor inhibitors (37–39), the outcome of
treatment in all patient groups may be different from that of
patients treated over 10 years ago. Use of current treatment
modalities, had they been available 10 years ago, would almost
certainly have minimized the early risk in patients with class
IIIC postinfarction unstable angina and would have brought
the long-term survival curves for stable and unstable angina
even closer together.
Clinical implications. The data provided no evidence of a
long-term predisposition toward recurrent unstable or isch-
emic events in patients with unstable angina pectoris treated by
coronary balloon angioplasty, despite what is now known about
systemic inflammatory markers and their persistence. The
rehospitalization rate was similar in patients with stable and
unstable angina over a 10-year period. Given that special care
is taken with high risk patients with refractory postinfarction
angina, coronary balloon angioplasty represents an effective
therapeutic strategy in patients with unstable angina pectoris
and is associated with an excellent long-term prognosis.
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